L.A. Business Journal

JANUARY 27, 2017

Snap could be courting more lawsuits as the tech giant moves forward on going public.

245

245

socalTECH

JANUARY 27, 2017

Pasadena-based Virtualitics , a new startup which provides data visualization in virtual reality (VR) and augmented reality (AR) environments, and says it uses machine learning and artificial intelligence, has raised $3M in a seed funding round. The funding came from un-named angel investors. Virtualics said its software is used to provide insights into "big and complex" data.

Artificial Inteligence 138

Artificial Inteligence CalTech Seed Funding Startup 138

L.A. Business Journal

JANUARY 27, 2017

Snap Inc. intends to publicly file for an IPO next week, according to Recode, putting it on track for a March offering.

126

126

socalTECH

JANUARY 27, 2017

Beverly Hills-based entertainment company STARZ , which is part of Lionsgate, said on Thursday afternoon that it has launched a new app on Amazon Fire TV. STARZ said its STARZ App gives users access to all of its original series, plus movies and first run films, on Amazon Fire TV and Fire TV Stick. The app requires an existing subscription to STARZ for accessing that content.

Beverly Hills 118

Beverly Hills Entertainment Content Company 118

Advertiser: Aggregage

Office leases are one of companies’ largest expenses, and if your whole team is working from home with no clear end in sight, you may be wondering what to do about your lease.

Company

L.A. Business Journal

JANUARY 27, 2017

About 30 percent of brand accounts on Snapchat are dormant, Virtualitics raises $3M to Visualize data in VR and AR, and SpaceX runs Hyperloop contest this weekend.

Snapchat 109

Snapchat SpaceX Report 109

socalTECH

JANUARY 27, 2017

Thousand Oaks-based biotech Amgen announced this morning that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has given its ADBP 501 (Biosilmilar Adalimumab) compouned a positive opinion for treatment of certain inflammatory diseases in adults. The company said the CHMP opinion is the first time an adalimumab biosimilar has been recommended for approval in the EU.

Thousand Oaks 109

Thousand Oaks Product Company Companies 109

socalTECH

JANUARY 27, 2017

Los Angeles-based online invitations service Evite says it has moved its headquarters to downtown Los Angeles, doubling the size of its corporate office. The company, which previously had its headquarters in West Hollywood, said the move goes to accomodate rapid growth at the company. Evite is part of Liberty Interactive. The company says it has moved to a new office in the 600 Wilshire building.

Evite 109

Evite West Hollywood Social Media Hollywood 109

L.A. Business Journal

JANUARY 27, 2017

Doorbell maker Bot Home rings up $109 million Series D round with eyes on IPO.

100

100

Xconomy

JANUARY 27, 2017

Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. The Cambridge, MA, company sold close to 6,365,000 shares at $16 apiece, almost 1 million more shares than it proposed to sell a few weeks ago. Jounce also priced above the $13 to $15 per share range it had set.

Pricing 63

Pricing San Diego Company Companies 63

Startup Professionals Musings

JANUARY 27, 2017

Customer service has traditionally been a support function to respond to customer initiated requests, meaning someone waits for the phone to ring or for a website support request form. Today’s customers definition of service is the sum total of their “experience,” covering all aspects of their relationship, including the shopping and buying process, as well as ongoing assistance.

Customer 95

Customer Custom Services Technical Review 95

Xconomy

JANUARY 27, 2017

It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender diversity in life sciences. Tensions continued to mount between drugmakers and payers over the rising costs of rare disease drugs. A flurry of deals took place, headlined by Johnson & Johnson’s $30 billion gamble on Swiss firm Actelion.

News 45

News Study Marketing Anthem 45